GBC’s Fry: Bioscience development requires persistence

Don Fry Commentary on WYPR Sun columnist Jay Hancock recently wrote about the importance of continued investment in Maryland’s biotech industry despite recession-related slowdowns in state funding, private-sector investment, and biotech development activity. He cites important distinctions about biotech that I’d like to amplify. Because Maryland has such robust...
Read More...

GBC’s Fry: Funding needed to push bioscience industry growth in Maryland

Don Fry Commentary on WYPR: In Maryland’s bioscience community, the line says it all. What line? The annual line of entrepreneurs that forms to apply for a limited amount of state tax credits made available on July 1 to investors in Maryland biotech companies. Last year, the line formed a day in advance for $6 million in available tax credits. This year, the line started five days early and a … Continue reading

Some successes for business emerge from difficult General Assembly session

Despite what has been a difficult session for both lawmakers and business advocates, a number of GBC-supported bills that will have a positive impact on Maryland’s business climate and economic growth gained passage, including measures to extend and improve the bioscience investment tax credit, provide local incentives for transit oriented development, and to strengthen the minority business enterprise program. Meanwhile, a bill to re-regulate electricity — which was strongly opposed … Continue reading

Three firms, two training programs garner Greater Baltimore Committee’s 2009 Bioscience Awards

Maryland biotech CEOs and companies were honored today by the Greater Baltimore Committee as winners of the region’s fourth bioscience award competition. Winners of the 2009 Bioscience Awards are: Best New Product or Progress: C. Randal Mills, Ph.D., president and CEO, Osiris Therapeutics, Inc. Mills’ Columbia-based company has spent more than $300 million developing stem cell therapies. The funding has allowed Osiris to complete clinical trials necessary to demonstrate the … Continue reading

Eighteen nominees vie for Greater Baltimore Committee’s 2009 Bioscience Awards

More than 150 leaders from Maryland’s bioscience industry and research community will attend a breakfast at the Renaissance Baltimore Harborplace Hotel to honor winners of the Greater Baltimore Committee’s 2009 Bioscience Awards. This is the fourth annual awards event presented by the Greater Baltimore Committee, the region’s most prominent organization of business and civic leaders, to recognize outstanding achievements in Maryland’s bioscience industry. The Greater Baltimore Committee has made support for … Continue reading

GBC Bioscience Committee members meet with Biotech Caucus

At the invitation of Legislative Biotech Caucus co-founder Delegate Dan Morhaim, three members of the GBC bioscience committee made presentations to the biotech caucus on February 11 in Annapolis. Steve Dubin, CEO of Martek, the global leader in infant formula supplements, told the caucus about Martek’s meteoric growth and the concomitant rise in the numbers of people the company employs. Early on Martek received state funds and Mr. Dubin pointed … Continue reading

GBC urges maintaining biotech tax credit, increasing it ASAP

The Greater Baltimore Committee has written a letter to Senate and House leaders urging them to at least maintain the amount of available tax credits for biotech investment at the budgeted level of $6 million and to significantly increase it as soon as economically practical. In announcing his BIO 2020 initiative last year, Governor O’Malley proposed doubling the tax credit in FY 2010 and doubling it again to $24 million in … Continue reading

GBC seeks nominations for fourth annual Bioscience Awards

The Greater Baltimore Committee is seeking nominations for the Fourth Annual Bioscience Awards to be held on March 12. Nominate a company or individual you know for an award.  The four award categories are: Entrepreneurial, Best New Product or Progress, Leadership in Bioscience, and President’s Award. Nominators will be asked to submit documentation and narratives that fulfill several criteria and then to add other supporting evidence as deemed suitable. Self-nominations … Continue reading

Media reports of UMB-GBC tech transfer initiative are overstated

A recent article and subsequent editorial in the Baltimore Business Journal regarding a partnership between the University of Maryland, Baltimore and the Greater Baltimore Committee to develop a business model to expedite bioscience tech transfer in Maryland do not accurately reflect the nature of this project. The intent of the GBC and UMB in starting a study to look at different potential models stems from our long-term interest in building … Continue reading

GBC’s Fry: Governor’s new bioscience plan worthy of lawmakers’ attention

Don Fry Commentary on WYPR Governor Martin O’Malley is on the right track with his proposal to quadruple available biotech investment tax credits in the next four years and to invest more than $1 billion over the next 10 years to grow our state’s bioscience industry. Other elements of his plan include expanding Maryland’s biotech incubator network, increasing the state’s stem cell research funding, expanding state venture investment, and strengthening … Continue reading